Angiogenic cytokines and growth factors in systemic sclerosis

Autoimmunity Reviews

Volumn 10, Issue 10, 2011, Pages 590-594

  Liakouli, Vasiliki ^a   Cipriani, Paola ^a   Marrelli, Alessandra ^a   Alvaro, Saverio ^a   Ruscitti, Piero ^a   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Angiogenesis; Angiogenic factors; Angiostatic factors; Systemic sclerosis; Vasculogenesis

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; BOSENTAN; CYTOKINE; ENDOSTATIN; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; KALLIKREIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UROKINASE RECEPTOR; VASCULAR ADHESION PROTEIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CAPILLARY DENSITY; CHRONIC DISEASE; HUMAN; HYPOXEMIA; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ANIMALS; AUTOIMMUNITY; CYTOKINES; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC;

EID: 80051667568     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.019     Document Type: Review

References (56)

1. LeRoy E.C. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996, 22:675-694.
2. Guiducci S., Giacomelli R., Matucci-Cerinic M. Vascular complication of scleroderma. Autoimmun Rev 2007, 6:520-523.
3. Distler O., Del Rosso A., Giacomelli R., Cipriani P., Conforti M.L., Guiducci S., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
4. Distler J., Hirth A., Kurowska-Stolarska M., Gay R.E., Gay S., Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003, 47:149-161.
5. Kuwana M., Okazaki Y., Yasuoka H., Kawakami Y., Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
6. Del Papa N., Quirici N., Soligo D., Scavullo C., Cortiana M., Borsotti C., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006, 54:2605-2615.
7. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
8. Wigley F.M. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009, 36:150-175.
9. Distler O., Distler J.H., Scheid A., Acker T., Hirth A., Rethage J., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-116.
10. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., et al. Conditional switching of VEGF provides new insights into adult neovascularization and proangiogenic therapy. EMBO J 2002, 21:1939-1947.
11. D'Alessio S., Fibbi G., Cinelli M., Guiducci S., Del Rosso A., Margheri F., et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004, 50:3275-3285.
12. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006, 26:1712-1720.
13. Allanore Y., Borderie D., Airo P., Guiducci S., Czirják L., Nasonov E.L., et al. Lack of association between 3 vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis 2007, 66:257-259.
14. Wipff J., Kahan A., Hachulla E., Sibilia J., Cabane J., Meyer O., et al. Association between an endoglin gene polymorphism and systemic sclerosis related pulmonary arterial hypertension. Rheumatology 2007, 46:622.
15. Coral-Alvarado P.X., Garces M.F., Caminos J.E., Iglesias-Gamarra A., Restrepo J.F., Quintana G. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010.
16. Zymek P., Bujak M., Chatila K., Cieslak A., Thakker G., Entman M.L., et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 2006, 48:2315-2323.
17. Vrekoussis T., Stathopoulos E.N., Kafousi M., Cieslak A., Thakker G., Entman M.L., et al. Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta. Oncol Rep 2007, 17:1115-1119.
18. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17:1835-1840.
19. Gabrielli A., Svegliati S., Moroncini G., Luchetti M., Tonnini C., Avvedimento E.V. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev 2007, 7:121-126.
20. Klareskog L., Gustafsson R., Scheynius A., Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990, 33:1534-1541.
21. Ludwicka A., Ohba T., Trojanowska M., Yamakage A., Strange C., Smith E.A., et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995, 22:1876-1883.
22. Hummers L.K., Hall A., Wigley F.M., Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009, 36:576-582.
23. Bianco A., Poukkula M., Cliffe A., Mathieu J., Luque C.M., Fulga T.A., et al. Two distinct modes of guidance signalling during collective migration of border cells. Nature 2007, 448:362-365.
24. Reinmuth N., Rensinghoff S., Raedel M., Fehrmann N., Schwoppe C., Kessler T., et al. Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells. Int J Oncol 2007, 31:621-626.
25. Wyler von Ballmoos M., Yang Z., Völzmann J., Baumgartner I., Kalka C., Di Santo S. Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFRβ axis-mediated angiogenesis. PLoS One 2010, 5:e14107-e.
26. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
27. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
28. Salcedo R., Oppenheim J.J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003, 10:359-370.
29. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004, 35:233-245.
30. De Falco E., Porcelli D., Torella A.R., Straino S., Iachininoto M.G., Orlandi A., et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004, 104:3472-3482.
31. Cipriani P., Milia A.F., Liakouli V., Pacini A., Manetti M., Marrelli A., et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 2006, 54:3022-3033.
32. Manetti M., Liakouli V., Fatini C., Cipriani P., Bonino C., Vettori S., et al. Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. Ann Rheum Dis Mar 2009, 68(3):408-411. Epub 2008 Oct 17.
33. Abraham D., Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007, 9(Suppl 2):S2.
34. Kahaleh M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991, 34:978-983.
35. Kadono T., Kikuchi K., Sato S., Soma Y., Tamaki K., Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995, 287:439-442.
36. Abraham D.J., Vancheeswaran R., Dashwood M.R., Rajkumar V.S., Pantelides P., Xu S.W., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151:831-841.
37. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H., Schäfers H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002, 105:1034-1036.
38. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
39. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
40. Matucci-Cerinic M., Denton C.P., Furst D.E., Mayes M.D., Hsu V.M., Carpentier P., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-contro lled trial. Ann Rheum Dis 2011, 70:32-38.
41. Ashara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF induced postnatal neovascularization. Circ Res 1998, 83:233-240.
42. Kim I., Moon S.O., Park S.K., Chae S.W., Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001, 89:477-479.
43. Michalska-Jakubus M., Kowal-Bielecka O., Chodorowska G., Bielecki M., Krasowska D. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford, England) 2010.
44. Fibbi G., Caldini R., Chevanne M., Pucci M., Schiavone N., Morbidelli L., et al. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab Invest 1998, 78:1109-1119.
45. Margheri F., Manetti M., Serratì S., Nosi D., Pucci M., Matucci-Cerinic M., et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006, 54:3926-3938.
46. Manetti M., Allanore Y., Revillod L., Fatini C., Guiducci S., Cuomo G., et al. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum 2011, 63:247-256.
47. Giusti B., Serrati S., Margheri F., Papucci L., Rossi L., Poggi F., et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005, 52:3618-3628.
48. Gruschwitz M., von den D.P., Kellner I., Hornstein O.P., Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992, 27:169-177.
49. Sollberg S., Peltonen J., Uitto J., Jimenez S.A. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992, 35:290-298.
50. Gruschwitz M.S., Hornstein O.P., von Den D.P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995, 38:184-1899.
51. Ihn H., Sato S., Fujimoto M., Kikuchi K., Kadono T., Tamaki K., et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997, 36:1270-1275.
52. Kiener H., Graninger W., Machold K., Aringer M., Graninger W.B. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 1994, 12:483-487.
53. Ihn H., Sato S., Fujimoto M., Takehara K., Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998, 37:1188-1192.
54. Stratton R.J., Coghlan J.G., Pearson J.D., Burns A., Sweny P., Abraham D.J., et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998, 91:561-566.
55. Mulligan-Kehoe M.J., Drinane M.C., Mollmark J., Casciola-Rosen L., Hummers L.K., Hall A., et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007 Oct, 56(10):3448-3458.
56. Macko R.F., Gelber A.C., Young B.A., Lowitt M.H., White B., Wigley F.M., et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002, 29:2565-2570.